This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

Disability accumulation may occur independently of relapses for some patients in the early phase of relapsing-remitting multiple sclerosis (MS), according to new research. Approximately 61% of ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

Disease-modifying treatments (DMTs) are the gold standard of multiple sclerosis (MS) therapy. They’ve been extensively researched, leading to an evidence base substantiating their efficacy through ...

DelveInsight's, “Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results from the EVOLVE-MS-1 study show Vumerity was ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

– Approval based on data from the randomized, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen – – Shorter infusion time will further improve the ...